From an immunotherapeutic perspective, PACA nanoparticles can be engineered to deliver immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies), tumor-associated antigens, or immune adjuvants, thereby promoting antigen presentation and T-cell activation (Table 1). Here, PDCD1 is linked to neoplasm.